BV can return even after treatment is taken correctly. Several factors may contribute, including persistent bacterial communities, changes in the vaginal microbiome and exchange of BV-associated bacteria between partners. Take the prescribed course as directed, and seek reassessment if symptoms persist or return. Recurrence is not proof that you did something wrong. Here are the treatment and prevention options to discuss with your clinician.
There is no single universally used definition of recurrent BV. Three or more symptomatic episodes in a year is a commonly used threshold for discussing recurrent disease and a longer-term plan.
BV-associated bacteria can form communities called biofilms. Persistent bacterial communities may contribute to recurrence, alongside changes in the vaginal microbiome and exchange of bacteria between partners. No single mechanism explains every recurrence.
Healthy vaginal microbiomes are dominated by lactobacilli (particularly Lactobacillus crispatus), which produce lactic acid that keeps pH below 4.5 and suppresses anaerobic bacterial growth. After BV, it takes time for lactobacilli to re-establish. During that window, anything that further disrupts them — new sexual partners, douching, scented products, antibiotics for other reasons, even menstruation — can tip the ecosystem back toward Gardnerella dominance.
BV isn't classified as an STI, but sexual activity is strongly associated with recurrence. New or multiple partners, sex without condoms, and receptive oral sex all correlate with higher recurrence rates. Male partners can harbor Gardnerella-associated bacteria (without symptoms) and potentially re-expose the patient.
For people with multiple confirmed recurrences, CDC describes suppressive vaginal metronidazole as one option a clinician may consider after treatment of the active episode. Benefit may not persist after suppression stops. The plan, duration and follow-up should be individualized; recurrence is not an automatic instruction to begin suppression.
With repeated confirmed BV, an ongoing clinician may consider suppressive vaginal metronidazole. Other selected regimens combine an oral antibiotic, a course of vaginal boric acid and later suppression; the supporting evidence is limited. This is a coordinated prescription plan, not a reason to start over-the-counter boric acid on your own. Boric acid must never be swallowed and should not be used during pregnancy.
Different antibiotics may be considered for selected recurrent episodes. Longer-term prevention requires confirmation of the cause and an individualized plan; do not add antibiotic doses around sex or menstruation on your own.
Avoid douching and internal vaginal washes. They can disturb the vaginal bacterial community and are associated with BV and relapse. Gently clean the external vulva and avoid products that irritate you.
Discuss concurrent treatment with an ongoing partner. The 2025 StepUp trial studied combined oral and topical antibiotics for male partners, and newer ACOG and NYSDOH guidance supports partner treatment to reduce recurrence. This is different from older trials of oral antibiotics alone. Bidwell offers eligible adult male partners a separate clinician-reviewed visit; the patient with recurrent vaginal symptoms may still need testing and a longer-term plan with an OB/GYN.
Any antibiotic course — for a cough, sinus infection, dental work — can disrupt vaginal lactobacilli for weeks. When antibiotic use is necessary, it's necessary, but avoid unnecessary prescriptions. This is part of the case for antibiotic stewardship generally.
Scented products, deodorant tampons, scented panty liners, fabric softener on underwear, and even some condoms with spermicide can irritate vaginal mucosa and shift the microbiome. Unscented, fragrance-free everything for anything touching the vulva.
Probiotics for recurrent BV: encouraging research, product-specific results. A randomized trial of vaginal Lactobacillus crispatus CTV-05 (Lactin-V), used after metronidazole, found BV recurrence by 12 weeks in 30% of participants versus 45% with placebo. A 2022 review of ten randomized trials also found a recurrence reduction, but products and study methods varied. These results do not prove that an arbitrary oral or vaginal supplement has the same benefit. Probiotics do not replace treatment for active BV; discuss any product with your clinician, especially if you have a weakened immune system. Lactin-V trial; 2022 systematic review.
Bidwell considers an acute recurrent BV episode individually. The clinician reviews the available history and determines whether online treatment is reasonable or testing is needed. Long-term suppression is outside this routine visit and needs ongoing care. For repeated vaginal episodes, discuss:
That's a longitudinal primary-care or OB/GYN relationship, not a one-visit online transaction.
BV can return even after treatment is taken correctly. Several factors may contribute, including persistent bacterial communities, changes in the vaginal microbiome and exchange of BV-associated bacteria between partners. Take the prescribed course as directed, and seek reassessment if symptoms persist or return. Recurrence is not proof that you did something wrong.
An ongoing male partner should discuss treatment with a clinician, especially for recurrent symptomatic BV. Updated guidance supports concurrent partner treatment, including when the male partner has no symptoms. Bidwell evaluates eligible adult male partners through their own $45 online visit. Partners with vaginal symptoms need their own evaluation and treatment plan.
Yes, at least once. BV increases susceptibility to STIs, and STI exposure can trigger BV episodes. A full panel (chlamydia, gonorrhea, trichomoniasis, HIV) is reasonable at the start of a recurrent-BV workup.
If episodes seem tied to your period or sex, tell your clinician. Confirming the cause and reviewing an ongoing prevention plan is more useful than starting extra antibiotic gel after every trigger on your own.
Bidwell offers eligible ongoing male partners their own $45 online assessment to help reduce recurrence in a partner with clinician-diagnosed BV. This does not replace evaluation of repeated vaginal symptoms or an OB/GYN's suppressive treatment plan. Coordinate the two people's care and treatment timing.
Current partner-treatment guidance.
Male partner treatment: eligibility, regimen and safety precautions. Adults must be physically in a supported state; medication is separate and prescriptions depend on clinician review.